Rhodamine 123 requires carrier-mediated influx for its activity as a P-glycoprotein substrate in Caco-2 cells

被引:119
作者
Troutman, MD [1 ]
Thakker, DR [1 ]
机构
[1] Univ N Carolina, Sch Pharm, Div Drug Delivery & Disposit, Chapel Hill, NC 27599 USA
关键词
P-glycoprotein; rhodamine; 123; doxorubicin; intestinal absorption; intestinal secretion;
D O I
10.1023/A:1025096930604
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Purpose. The purpose of this work was to elucidate transport pathways of the P-glycoprotein (P-gp) substrates rhodamine 123 (R123) and doxorubicin across Caco-2 cells. Methods. Experiments were designed to identify saturable and nonsaturable transport processes and transport barriers for R123 and doxorubicin transport across Caco-2 cells. Confocal laser scanning microscopy (CLSM) imaged R123 transport under normal conditions and in the presence of the P-gp inhibitor, GW918 ( used to abolish P-gp-mediated efflux activity). Results. R123 secretory P-app (P-app,P- BA) showed concentration dependence, whereas R123 absorptive P-app (P-app,P- AB) did not. Inhibition of P-gp efflux revealed that P-gp-mediated efflux had no effect on R123 or doxorubicin P-app,P- AB, but enhanced R123 and doxorubicin Papp, BA. In calcium-free medium, R123 P-app,P- AB increased 15-fold, indicating intercellular junctions are a barrier to R123 absorption. CLSM of R123 fluorescence during absorptive transport under normal conditions and in the presence of GW918 was identical, and was limited to paracellular space, confirming that P-gp is not a barrier to R123 absorption. CLSM revealed that R123 fluorescence during secretory transport under normal conditions and in the presence of GW918 was localized intracellularly and in paracellular space. R123 and doxorubicin uptake across Caco-2 cells basolateral membrane was saturable. Conclusions. R123 absorptive transport occurs primarily by paracellular route, whereas R123 secretory transport involves influx across BL membrane mediated solely by a saturable process followed by apically directed efflux via P-gp. Doxorubicin utilizes similar transport pathways to cross Caco-2 cells.
引用
收藏
页码:1192 / 1199
页数:8
相关论文
共 40 条
[1]   UNIDIRECTIONAL FLUXES OF RHODAMINE-123 IN MULTIDRUG-RESISTANT CELLS - EVIDENCE AGAINST DIRECT DRUG EXTRUSION FROM THE PLASMA-MEMBRANE [J].
ALTENBERG, GA ;
VANOYE, CG ;
HORTON, JK ;
REUSS, L .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (11) :4654-4657
[2]   Drug exsorption from blood into the gastrointestinal tract [J].
Arimori, K ;
Nakano, M .
PHARMACEUTICAL RESEARCH, 1998, 15 (03) :371-376
[3]   EVIDENCE FOR A POLARIZED EFFLUX SYSTEM IN CACO-2 CELLS CAPABLE OF MODULATING CYCLOSPORINE-A TRANSPORT [J].
AUGUSTIJNS, PF ;
BRADSHAW, TP ;
GAN, LSL ;
HENDREN, RW ;
THAKKER, DR .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1993, 197 (02) :360-365
[4]   What have we learnt thus far from mice with disrupted P-glycoprotein genes? [J].
Borst, P ;
Schinkel, AH .
EUROPEAN JOURNAL OF CANCER, 1996, 32A (06) :985-990
[5]   CLASSICAL AND NOVEL FORMS OF MULTIDRUG-RESISTANCE AND THE PHYSIOLOGICAL FUNCTIONS OF P-GLYCOPROTEINS IN MAMMALS [J].
BORST, P ;
SCHINKEL, AH ;
SMIT, JJM ;
WAGENAAR, E ;
VANDEEMTER, L ;
SMITH, AJ ;
EIJDEMS, EWHM ;
BAAS, F ;
ZAMAN, GJR .
PHARMACOLOGY & THERAPEUTICS, 1993, 60 (02) :289-299
[6]   Potential role of P-glycoprotein in affecting hepatic metabolism of drugs [J].
Chiou, WL ;
Chung, SM ;
Wu, TC .
PHARMACEUTICAL RESEARCH, 2000, 17 (08) :903-905
[7]   Carrier-mediated uptake of rhodamine 123: Implications on its use for MDR research [J].
Cho, CW ;
Liu, Y ;
Yan, XD ;
Henthorn, T ;
Ng, KY .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2000, 279 (01) :124-130
[8]  
Collett A, 1999, J PHARMACOL EXP THER, V288, P171
[9]   CHARACTERIZATION OF ACTINOMYCIN-D-RESISTANT CHO CELL-LINES EXHIBITING A MULTIDRUG-RESISTANCE PHENOTYPE AND AMPLIFIED DNA-SEQUENCES [J].
DIDDENS, H ;
GEKELER, V ;
NEUMANN, M ;
NIETHAMMER, D .
INTERNATIONAL JOURNAL OF CANCER, 1987, 40 (05) :635-642
[10]   Inhibition of P-glycoprotein by D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS) [J].
Dintaman, JM ;
Silverman, JA .
PHARMACEUTICAL RESEARCH, 1999, 16 (10) :1550-1556